{"id":"W4385644744","doi":"10.1182/bloodadvances.2023010151","title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Genentech; Italfarmaco; Swedish Orphan Biovitrum; Grifols; Actuate Therapeutics; Galecto; Sierra Oncology; Pfizer; Incyte; CTI Biopharma; Bristol-Myers Squibb; Constellation Pharmaceuticals; Acceleron; Astellas Pharma; Ionis Pharmaceuticals; Jazz Pharmaceuticals; Alexion Pharmaceuticals; Karyopharm Therapeutics; National Cancer Institute; Gilead Sciences; Sanofi; MorphoSys; Celgene; AstraZeneca; Amgen","keywords":"Ruxolitinib; Anemia; Myelofibrosis; IC50; Medicine; Pharmacology; Cmax; Potency; Internal medicine; Chemistry; Pharmacokinetics; Bone marrow; Biochemistry; In vitro","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003588353,0.0002576593,0.00049049,0.0001617274,0.0001555166,0.0003568031,0.000160407,0.0001684112,0.001973914],"category_scores_gemma":[0.0003882802,0.0000770376,0.0002340729,0.0001576439,0.00009064814,0.0002408915,0.0001563567,0.0007487365,0.0002265931],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002638653,"about_ca_system_score_gemma":0.0003289068,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003320929,"about_ca_topic_score_gemma":0.001332858,"domain_scores_codex":[0.9998723,0.00003776212,0.00001213756,0.00002198594,0.000030377,0.00002531735],"domain_scores_gemma":[0.9998515,0.00003883262,0.00003199726,0.00001014665,0.00001316757,0.000054458],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.04231,0.003552872,0.04525123,0.000850625,0.0007694117,0.001436755,0.0002727174,0.002004466,0.271576,0.001249606,0.0108145,0.6199118],"study_design_scores_gemma":[0.03197614,0.1732273,0.5185354,0.0002907659,0.001635409,0.0165038,0.0003856414,0.009919972,0.1464446,0.001902451,0.09906251,0.0001159167],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9772285,0.01166044,0.0009052977,0.000766949,0.00006342321,0.0002255328,0.0006782711,0.000110109,0.008361503],"genre_scores_gemma":[0.9942479,0.001613511,0.001102355,0.0005391943,0.0000861246,0.0000939257,0.0008407359,0.000009876528,0.001466359],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001973914,"threshold_uncertainty_score":0.00660342,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006939995416863052,"score_gpt":0.2316811282671716,"score_spread":0.2247411328503086,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}